InvestSMART

Lumos Diagnostics Holdings Limited (ASX:LDX)

ALERT: Price-sensitive ASX Announcement for LDX
Current share price for LDX : $0.100 -0.095 (-48.72%)+
Announcement
Release
20 Apr 2026 9:49AM
Price at Release
$0.195
Full Release
download
Summary
Lumos Diagnostics Holdings Limited reported significant advancements in its third quarter of FY26, highlighted by the US FDA's 510(k) clearance with CLIA waiver for its FebriDx® test, expanding its market potential considerably. The company achieved milestone payments totaling US$5.72 million and saw a revenue increase of 37% year-over-year for Q3, reaching US$4.8 million. Despite an operating cash outflow of US$2.8 million, Lumos bolstered its cash position through a A$20 million placement, ending the quarter with a cash balance of US$1.1 million. The company continues to prioritize FebriDx® sales growth, the BARDA-funded paediatric study, and the Hologic fFN project.
Key Points
  • FebriDx® received US FDA 510(k) clearance with a CLIA waiver, expanding its market reach significantly.
  • Milestone payments were triggered by the successful 510(k) application, totaling US$5.72 million.
  • Revenue for Q3 FY26 was US$4.8 million, a 37% increase compared to the previous corresponding period.
  • Operating cash outflow for the quarter was US$2.8 million, with investments in inventory production.
  • Lumos completed a A$20 million placement to strengthen its financial position.
  • Cash balance at the end of Q3 FY26 was US$1.1 million, with additional funding expected from milestone payments.
  • The Share Purchase Plan (SPP) offered additional shares to eligible shareholders with benefits attached.
  • Continued focus on increasing FebriDx® sales in the US, progressing the BARDA paediatric study, and Hologic fFN project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.